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Discovery. 1:126, 2004; Exp Hematol. 32:470, 2004; Exp Hematol.
32:300, 2004; Stem Cells. In press). In this ﬁrst phase I clinical trial
of CTCE-0214, the safety, tolerability, pharmacokinetic proﬁle,
and the pharmacodynamic effects of single subcutaneous doses of
CTCE-0214 given to healthy subjects were studied. The random-
ized, double-blinded, placebo-controlled dose-escalation trial en-
rolled 24 subjects in 6 dose-escalation groups. Four healthy human
subjects in each cohort received either CTCE-0214 or Placebo,
randomized in a 3:1 ratio. The doses of CTCE-0214 were 0.2
mg/kg, 0.5 mg/kg, 0.8 mg/kg, 1.5 mg/kg, 2.0 mg/kg, and 3.0
mg/kg. CTCE-0214 was shown to be safe with no serious adverse
events reported. The most common drug related adverse events
were injection site pain and erythema, which were transient and
resolved without intervention. The severity of injection site pain
appeared to be associated with the overall quantity of study drug
administered. Moderate or severe pain was reported only at 80 mg
or greater of CTCE-0214 per syringe. Dilution across more than
one syringe appeared to effectively reduce injection site pain.
Pharmacokinetic analysis of CTCE-0214 plasma concentrations
showed that Tmax was reached at 0.25 hours post-administration
for all CTCE-0214 treated cohorts. The apparent terminal elim-
ination half-life (t1/2) values were estimated to be 0.41 to 0.32
hours. CTCE-0214 administration was associated with signiﬁcant
dose-dependent increases in total white blood cell and neutrophil
counts in treated subjects, peaking at around 6 hours post-injec-
tion. In the 3.0 mg/kg arm, the mean difference in neutrophil
count from baseline was more than three times that of the Placebo
arm. The same trend was apparent in the 2.0 and 1.5 mg/kg arms.
These results suggest that SDF-1 agonists may potentially be used
in patients with low neutrophil count receiving chemotherapy with
or without the use of G-CSF. The potential for CTCE-0214 to
mobilize neutrophils and other blood cells merits serious consid-
eration.
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DYSKERATOSIS CONGENITA: A HUMAN MODEL TO STUDY THE ROLE
OF TELOMERASE AND TELOMERE LENGTH IN HEMATOPOIESIS
Goldman, F.D.1, Cooper, S.R.1, Singhal, V.1, Klingelhutz, A.2,
Lansdorp, P.3, Schlueter, A.4 1. University of Iowa Children’s Hospital;
2. University Iowa, Department of Microbiology; 3. University of British
Columbia, Department of Medicine; 4. University of Iowa, Department
of Pathology.
Dyskeratosis congenita (DC) is an inherited multisystem disorder
of premature aging characterized by early bone marrow (BM)
failure. This disease is due to telomerase defects resulting in telo-
mere shortening and premature senescence of various somatic
cells, particularly those from highly proliferative tissues. Telomer-
ase plays an important though not fully understood role in hema-
topoiesis. We have recently identiﬁed a three-generation kindred
with autosomal dominant DC with affected individuals having a
single gene deletion of the RNA component of telomerase,
hTERC, and recent third generation patients are displaying signs
of BM dysfunction at an earlier age than their affected parents. To
explain these ﬁndings, we hypothesize that early BM failure in DC
may be due to a proliferative/differentiative defect in hematopoi-
etic stem cells (HSC) as a consequence of telomere shortening.
Five patients (age 11–50) from 2 successive generations have thus
far been enrolled on a study that allows collection of HSC by
leukopheresis. All patients had clinical and laboratory features of
DC, including signiﬁcant BM hypocellularity (10–30%). The per-
centage of CD34 cells in the G-CSF primed leukopheresis prod-
uct was signiﬁcantly lower in DC subjects (0.05–0.24%) compared
to controls (0.7–1.2%). Extensive immunophenotyping of HSC
revealed a higher percentage of CD33/CD34 cells in DC
subjects (60–97%) relative to controls (9–28%). HSC function was
examined in vitro by a clonogenic progenitor cell assay, assessing
percent, number, and morphology of colony forming units (CFU).
Of note, 2/5 DC subjects (both third generation) had a markedly
reduced number of CFU, and percentage of CFU-GM and CFU-
GEMM were decreased in 4/5 DC subjects relative to controls. To
assess DC HSC function in vivo, CD34 HSC from 2 different
DC subjects and age-matched controls were injected into suble-
thally irradiated NOD-SCID mice. None of the mice injected with
DC HSC showed evidence of human hematopoiesis at up to 20
weeks post injection, while animals receiving control HSC had
evidence of human hematopoiesis by 6 weeks. In conclusion, DC is
an excellent human model to assess the role of telomerase and
telomere shortening in hematopoiesis. Importantly, there appears
to be a correlation of the DC clinical phenotype and DC HSC
function with telomere length. Further studies are needed to de-
termine whether the aberrant function of DC HSC can be rescued
by a gene-transfer approach.
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GLYCOGEN SYNTHASE KINASE-3 IS AN IN VIVO REGULATOR OF HU-
MAN HEMOPOIETIC STEM CELLS
Trowbridge, J.J.1, Xenocostas, A.2, Moon, R.T.3, Bhatia, M.1 1. Krem-
bil Centre for Stem Cell Biology, Robarts Research Institute, London,
ON, Canada; 2. London Health Sciences Centre & The University of
Western Ontario, London, ON, Canada; 3. Howard Hughes Medical
Institute & The University of Washington School of Medicine, Seattle,
WA.
Hemopoietic stem cells (HSCs) are rare cells of the hemopoietic
system with the ability to self-renew and differentiate into mature
blood cells. The application of HSC transplantation as a curative
intervention can be limited by the lack of a suitable donor or the
suboptimal collection of HSCs. Umbilical cord blood (UCB) cells
have potential as a readily available alternate source of HSCs but at
present have limited utility in adult recipients because the relatively
low numbers of HSCs can lead to delayed hemopoietic reconsti-
tution. At present, there exists no therapeutic intervention that
allows for the in vivo expansion of transplanted HSCs. We exam-
ined the effects of inhibiting glycogen synthase kinase-3 (GSK-3),
a constitutively active serine/threonine kinase, on the regulation of
the human HSC pool. Primitive lineage-depleted (Lin-) neonatal
UCB cells or adult G-CSF mobilized peripheral blood (M-PB)
cells were intravenously injected into sublethally irradiated NOD/
SCID mice. The mice were then treated with either 30 mg/kg of
a GSK-3 inhibitor or with vehicle twice per week for the duration
of the 5 to 6 week transplant period. NOD/SCID recipients
treated with the GSK-3 inhibitor demonstrated an increased fre-
quency and total number of primitive human HSCs (CD45
CD34) after transplantation of UCB-derived HSCs compared to
vehicle-treated controls. The mean number of HSCs in the bone
marrow were 12791  2892 versus 62374  15533, respectively,
(mean  SEM; P  .02; N  4 mice/group). To further charac-
terize the effect of GSK-3 inhibition on human HSC repopulating
capacity, sorted CD45 human hematopoietic cells from the re-
constituted mice were plated in a functional clonogenic in vitro
assay. Hemopoietic cells derived from recipients reconstituted with
UCB or M-PB-HSCs and treated with GSK-3 inhibitor generated
greater numbers of HSC-colony forming units (HSC-CFU) than
untreated controls (mean  SEM: 2121  526 versus 1021  356;
respectively. P .038, N 7). The developmental potential of the
HSC-CFU to form mature colonies of various subtypes (erythroid,
granulocyte, macrophage, and granulocyte-macrophage) was not
altered by the treatment. Our results demonstrate that GSK-3 can
modulate HSC activity in vivo and suggest that administration of
GSK-3 inhibitor may provide a clinical means to directly enhance
the repopulating capacity of transplanted HSCs.
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NOGENIC AND DISPLAY IMMUNOSUPPRESSIVE PROPERTIES ON ACTI-
VATED T CELLS
Kovacsovics-Bankowski, M.1, Streeter, P.R.1, Van’t Hof, W.J.2,
Deans, R.J.2, Maziarz, R.T.1 1. OHSU, Portland, OR; 2. Athersys,
Cleveland, OH.
Multipotent Adult Progenitor cells (MAPC) are nonhematopoi-
etic stem cells, present within the bone marrow that can be grown
extensively and can be induced to generate cells with phenotypic
characteristics and gene proﬁle of cells derived from endoderm,
ectoderm and mesoderm. The capacity to differentiate into these
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diverse cell types distinguishes MAPC from Mesenchymal Stem
Cells (MSC), and suggests that MAPCs may therefore be an ideal
cell for in vivo therapies for tissue repair or regeneration in mul-
tiple organ systems (Jiang Y et al Nature, 2002; 418:41–49). We
have developed the technology for the large-scale expansion of
MAPC with stable phenotype and biological properties. Under
these conditions, cell surface marker analysis of MAPC revealed
that these cells are positive for CD10, CD90, and CD49c, they are
weakly positive for MHC class I, and are negative for MHC class
II, CD45, and CD106, indicating that MAPC are not derived from
the hematopoietic lineage. However, to optimize in vivo utiliza-
tion, the understanding of immunological properties of MAPC is
critical. Thus, we undertook an analysis of MAPC immunogenic-
ity. First, these stem cells were shown to be non-immunogenic as
MAPC from two different rat strains did not stimulate allogeneic T
cell proliferation, while splenocytes of the same rat strains elicited
strong proliferative responses in a mixed lymphocytic culture.
Second, MAPC displayed immunosuppressive properties. Addition
of MAPC at the initiation of a mixed lymphocyte reaction (MLR)
suppressed T cell proliferation in a dose dependent manner. The
inhibition was detectable when number as low as 3000 MAPC/well
were added to 1 105 T cell responder. Lymphocyte proliferation
in MAPC-containing cultures was inhibited by up to 80% when
compared to cultures without MAPC. The ability to inhibit T cell
alloresponse was independent of the MHC, allowing the use of
third party MAPC as inhibitory cells. MAPC also inhibited pro-
liferative responses to the T cell mitogen Concanavalin A (50%),
although inhibition required higher MAPC:responder cell ratios.
Taken together, these data suggest that MAPC are progenitor cells
that do not express markers of the hematopoietic lineage; they are
non-immunogenic to T cells, suggesting that universal MAPC
donors may be used for tissue repair or regeneration; and MAPC
exhibit potent immunosuppressive properties, a result which sug-
gests that these calls may be useful in the management and/or
prevention of GVHD.
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Leung, L.1, Thomson, S.3, Hennessy, A.3, Rasko, J.1,4 1. Centenary
Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia;
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NSW, Australia; 3. Renal Department, Royal Prince Alfred Hospital,
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Hospital, Sydney, NSW, Australia.
Mesenchymal stem cells (MSC), as well as showing promise for
tissue regeneration and gene therapies, have the potential to facil-
itate bone marrow transplantation. First, they can provide stromal
support for engrafted cells, and second, their immunologic prop-
erties may facilitate engraftment and reduce graft versus host
disease. Much is made of the ease with which MSC can be cultured
and expanded many-fold in vitro, however there is evidence that
this can alter the fundamental properties of these cells. Therefore,
we have explored the potential to increase the number of marrow
MSC in vivo using various cytokine regimens in a nonhuman
primate (NHP) model. Male baboons between 7 and 11 years of
age received subcutaneous cytokines as follows: (1) G-CSF 100
mcg/kg/day for 5 days; (2) pegylated G-CSF (pegG-CSF), single
dose 300 mcg/kg day 5; (3) G-CSF 100 mcg/kg/day  stem cell
factor (SCF) 50 mcg/kg/day for 5 days; and (4) pegylated
megakaryocyte growth and development factor (pegMGDF) 1
mcg/kg second daily for 10 days  G-CSF 100 mcg/kg/day for 5
days starting day 5 before the harvest. Bone marrow was aspi-
rated from the iliac crest at baseline and on the ﬁnal day of cytokine
administration. Mononuclear cells were isolated on Ficoll-Paque
Plus, and plated in triplicate in alpha-MEM plus 20% FCS for
ﬁbroblast colony forming cells (CFU-F). Cells were ﬁxed, stained,
and scored on day 7, and the number of CFU-F/mL of bone
marrow was then calculated. The mean baseline CFU-F marrow
concentration was 2 032/mL (n  15). There was an increase in
CFU-Fs following each of the cytokine regimens to 11 427/mL, 8
430/mL, 20 662/mL, and 15 745/mL after G-CSF (n  3, P 
.001), pegG-CSF (n 4, P	 .05), G-CSFSCF (n 5, P .001),
and G-CSFpegMGDF (n  4, P  .01) compared to baseline,
respectively. We also explored the potential for the mobilization of
MSC into peripheral blood. CFU-F were not detected in baseline
peripheral blood mononuclear cells (PBMNC) samples from any
animal. However, CFU-F were detected in 3 animals after
G-CSFSCF at a frequency of 0.8/mL to 1.5/mL, but no other
cytokine regimen. In conclusion, these data conﬁrm that cytokine
regimens used to mobilize hemopoietic stem cells can be used to
induce in vivo expansion and mobilization of MSC and that the
combination of G-CSF and SCF may be the most effective.
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MODULATION OF ALDEHYDE DEHYDROGENASE ACTIVITIY AND RETI-
NOID SIGNALING INDUCES HEMATOPOIETIC STEM CELL SELF RE-
NEWAL
Muramoto, G.1, Saﬁi, R.1, Chao, N.J.1, Colvin, M.1, McDonnell, D.1,
Chute, J.P.1 Duke University, Durham, NC.
Aldehyde dehydrogenases are cytosolic enzymes that convert
aldehydes into carboxylic acids. Human aldehyde dehydrogenase 1
(ALDH1) is highly expressed in the liver and in hematopoietic
stem cells (HSCs). Although ALDH1 is a selectable marker of
HSCs, its HSC-speciﬁc function is unknown. We hypothesized
that ALDH might play a critical role in HSC fate determinations
since it is required for the production of retinoic acids, which are
broadly implicated in tissue differentiation, tissue patterning, and
embryonic development in vertebrates. In this study, highly puri-
ﬁed human CD34CD38lin HSCs were cultivated with early
acting cytokines, thrombopoietin, stem cell factor, and Flt-3 ligand
(TSF) in the presence or absence of the competitive ALDH inhib-
itor, diethylaminobenzaldehyde (DEAB). Treatment of human
BM and CB HSCs with TSF caused a loss of CD34CD38 cells
in culture, morphologic differentiation, ampliﬁcation of commit-
ted colony forming cells (CFCs), and a loss of primitive cells
capable of repopulating non-obese diabetic/severe combined im-
munedeﬁcient mice (SCID-Repopulating Cells, SRCs). Con-
versely, culture of BM and CB HSCs with TSF plus 100 M
DEAB blocked the morphologic differentiation and lineage com-
mitment of HSCs in culture, expanded the CD34CD38 pop-
ulation, and ampliﬁed SRCs 2- to 4-fold compared to input, indi-
cating a fundamental role for ALDH activity in HSC
differentiation. The effects of DEAB could be reversed by the
co-administration of the retinoic acid receptor (RAR) agonist,
all-trans retinoic acid (ATRA), suggesting that the ability of
ALDH to produce retinoic acids is important in determining HSC
fate. Via screening studies of direct ligands of RAR and RXR, we
also identiﬁed a selective RXR modulator, LGD101506, which
functioned similarly to DEAB in impeding HSC differentiation
and causing the 4-fold expansion of SRCs. Interestingly, both
DEAB treatment and LGD101506 reversed the down-modulation
of HOXB4 transcription that was otherwise observed in
CD34CD38lin cells during culture with cytokines, suggest-
ing that inhibition of ALDH or RXR modulation may promote
HSC self-renewal via discrete interactions with other regulatory
pathways. Modulation of ALDH activity and retinoid signaling is a
novel and effective strategy to amplify human HSCs.
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DEXAMETHASONE ENHANCES ERYTHROPOIETIC DIFFERENTIATION OF
EMBRYONIC STEM CELLS
Srivastava, A.S.1, Kaushal, S.1, Carrier, E.1 University of California
San Diego, La Jolla, CA.
We have studied the in vitro differentiation of murine embryonic
stem cells (ES) towards erythropoiesis and expression of genes
during this process. It has been reported that dexamethasone di-
rects ES cells towards erythrocytic differentiation but the mecha-
nism of gene regulation induced by dexamethasone is not well
understood. We hypothesized that dexamethasone induces up-
regulation of erythropoietic genes such as GATA-1, FLK-1,
EPO-R, and directs ES cells towards erythropoietic differentiation.
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